Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6402 posts found.

pharmafocus_march_2019_cover

Read the March 2019 issue of Pharmafocus online now!

February 26, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Drug pricing, HIV, Trump, WHO, brexit, depression, mental health, pharmacovigilance, rare disease

Just one month to go until Brexit here in the UK, and it’s still all to play for. After months …
News

Living with melanoma after surgery

February 25, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, melanoma, patient experience, pharma

Dr Elizabeth Walmsley was left lost when she received her melanoma diagnosis. Thankfully, through perseverance and the advice of friends …
Feature
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

February 22, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, China, MedImmune, Xeljanz, asthma, diabetes, keytruda, osteoarthritis, pharma, rare disease

Happy Friday! With the weekend within reach, check out our run-down of the top ten most popular articles on Pharmafile.com …
News

US Department of Justice investigate J&J over Baby Powder allegations

February 22, 2019 Medical Communications Cancer, J&J, JJ, Johnson and Johnson, USA, asbestos, oncology, talc

The Justice Department and US Securities and Exchanges Commission are investigation healthcare giant Johnson & Johnson over allegations that Johnson’s …
News
img_4190-e1376666350337-web

MHRA warns of congenital malformation risk of neo-mercazole during pregnancy

February 22, 2019 Medical Communications, Research and Development MHRA, neo-mercazole, pharma

UK drug watchdog The Medicines and Healthcare products Regulatory Agency (MHRA) has warned of the potential side-effects of Neo-mercazole (carbimazole) …
News

Genetically modified twins may have been altered in a way that improves memory and cognition

February 22, 2019 Medical Communications CCR5, HIV, cognitive enhancement, crispr, gene editing

The twins who were genetically modified using the gene editing tool CRISPR may have been changed in a way that …
News

Poison control calls for kratom increase from one a month to two a day, study shows

February 22, 2019 Medical Communications USA, herbal medicines, kratom, poison control, toxicology

The number of phone calls to US poison control centres over exposures to kratom – an herbal drug with opioid …
News
screen_shot_2019-01-29_at_15

Beating the flu

February 18, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing flu, influenza, pharma, seqirus

On 14 January, the European Commission issued marketing approval for Flucelvax Tetra, the first cell-based, quadrivalent influenza vaccine. Pharmafocus spoke …
Feature
diabetes-777001_960_720

Lilly and Boehringer’s Trajenta matches glimepiride in delaying cardiovascular events in type 2 diabetes patients

February 15, 2019 Medical Communications, Research and Development Boehringer, Eli Lilly, cardiovascular disease, pharma, type 2 diabetes

Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself …
News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

February 15, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AMR, Dame Sally Davies, FDA, FMD, antibiotic resistance, esketamine, falsified medicines, top 10

News that the FDA’s advisory panel had recommended Janssen’s intranasal esketamine spray Spravato as a treatment for treatment resistant depression, …
News

Roche’s Perjeta secures NICE approval in adjuvant HER2+ metastatic breast cancer

February 15, 2019 Medical Communications, Sales and Marketing NICE, Perjeta, Roche, pharma

NICE has announced its decision to authorise the use of Roche’s Perjeta (pertuzumab) on the NHS for the treatment of …
News

AstraZeneca to retire MedImmune brand amid restructuring

February 15, 2019 Medical Communications AstraZeneca, Business, MedImmune, R&D, biologics, restructuring

AstraZeneca is retiring the MedImmune brand as part of a restructuring that will see biologics integrated into two new R&D …
News

Lundbeck and Otsuka’s bipolar treatment fails Phase 3 trials due to unexpected placebo effect

February 15, 2019 Medical Communications CNS, Lundbeck, Otsuka, Rexulti, bipolar disorder, mental health

Lundbeck and Otsuka’s treatment for bipolar disorder, Rexulti, failed to achieve its primary endpoint in two separate Phase 3 trials. …
News
dr_nathwani_770x510

Sanofi name current CMO Dr Ameet Nathwani as new Chief Digital Officer

February 12, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

French firm Sanofi has appointed pharma veteran Dr Ameet Nathwani to the position of Chief Digital Officer. In his new …
Appointment
ai_pharmafocus

Solving the drug development problem

February 11, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, drug discovery, feature, pharma, pistoia alliance

Excitement is building for the potential of AI in just about every field, but how can it address pharma’s unique …
Feature
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025